Research Triangle Park
85 articles with TransEnterix
TransEnterix to Showcase Digital Laparoscopy with the Senhance Surgical System at Society of American Gastrointestinal and Endoscopic Surgeons 2019 Annual Meeting
TransEnterix, Inc. announced it will host several events highlighting digital laparoscopy with the Senhance™ Surgical System–the first new abdominal robotic surgery platform to receive FDA clearance since 2000–at the 2019 Annual Meeting of the Society of American Gastrointestinal and Endoscopic Surgeons April 3 – 6, 2019 in Baltimore, Maryland.
TransEnterix, Inc. Reports Operating and Financial Results for the Fourth Quarter and Full Year 2018
TransEnterix, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, announced its operating and financial results for the fourth quarter and full year 2018.
TransEnterix Schedules Fourth Quarter and Fiscal Year 2018 Financial and Operating Results Conference Call for February 26, 2019
TransEnterix, Inc. announced that it plans to release fourth quarter and fiscal year 2018 financial and operating results before the market opens on Tuesday, February 26, 2019.
Senhance Ultrasonic advanced energy capability broadens potential applicability of Senhance surgery in the United States
TransEnterix, Inc. announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California.
TransEnterix, Inc. today announced its naming to Deloitte’s 2018 Technology Fast 500TM, an annual ranking of the fastest growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors.
TransEnterix, Inc. (NYSE American:TRXC) announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the Stifel 2018 Healthcare Conference at The Lotte New York Palace Hotel in New York City.
TransEnterix Schedules Third Quarter 2018 Financial and Operating Results Conference Call for November 8, 2018
Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will host a conference call to discuss these results
10/19/2018TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry.
TransEnterix to Showcase First Digital Laparoscopic Surgical Platform, the Senhance Surgical System, at American College of Surgeons Clinical Congress 2018
Experience Senhance Surgery at TransEnterix Booth #577
Receives FDA 510(k) clearance for 3mm instrument set as well as additional 5mm instruments, advancing minimally invasive capabilities within digital laparoscopy
Announces four Senhance system sales in third quarter of 2018
Filed 510(k) submission for Senhance Ultrasonic, broadening the potential applicability of Senhance surgery in the U.S.
Total revenue of $6.4 million, including the sale of four Senhance Systems
TransEnterix Schedules Second Quarter 2018 Financial and Operating Results Conference Call for August 7, 2018
TransEnterix, Inc. announced that it plans to release second quarter 2018 financial and operating results before the market opens on Tuesday, August 7, 2018.
Announces fourth Senhance System sale in second quarter of 2018
Receives FDA 510(k) clearance for laparoscopic inguinal hernia and laparoscopic cholecystectomy procedures
TransEnterix Announces FDA 510(k) Submission for Senhance Indication Expansion to More than Double Addressable Market in the U.S. and Provides Commercial Update
TransEnterix today announced the Company has filed a FDA 510(k) submission to expand the indication for use of its Senhance Surgical System, and provided an update about commercial results thus far for the quarter ending March 31, 2018.
During the quarter ending December 31, 2017, the Company sold two Senhance Systems for total revenue of approximately $3.3 million.
TransEnterix announced that the Company has entered into an agreement with Great Belief International Limited (GBIL), to advance the SurgiBot System towards global commercialization.